Skip to main content

Table 1 The clinical manifestations of disease in each study group

From: The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study

Clinical symptoms and signs Study group
Number (%)
Control group
Number (%)
Blurred vision 3 (15) 8 (26.6)
Diplopia 4 (20) 4 (13.3)
Blindness 1 (5) 0 (0)
Gait problem 5 (25) 2 (6.6)
Paresthesia 3 (15) 2 (6.6)
Muscle weakness 0 (0) 3 (10)
Dysarthria 0 (0) 1 (3.3)
Bladder dysfunction 0 (0) 1 (3.3)